Abstract:Developing novel therapeutics and diagnostic tools based upon an understanding of neuroplasticity is critical in order to improve the treatment and ultimately the prevention of a broad range of nervous system disorders. In the case of mood disorders, such as major depressive disorder (MDD) and bipolar disorder (BPD), where diagnoses are based solely on nosology rather than pathophysiology, there exists a clear unmet medical need to advance our understanding of the underlying molecular mechanisms and to develop fundamentally new mechanism experimental medicines with improved efficacy. In this context, recent preclinical molecular, cellular, and behavioral findings have begun to reveal the importance of epigenetic mechanisms that alter chromatin structure and dynamically regulate patterns of gene expression that may play a critical role in the pathophysiology of mood disorders. Here, we will review recent advances involving the use of animal models in combination with genetic and pharmacological probes to dissect the underlying molecular mechanisms and neurobiological consequence of targeting this chromatin-mediated neuroplasticity. We discuss evidence for the direct and indirect effects of mood stabilizers, antidepressants, and antipsychotics, among their many other effects, on chromatin-modifying enzymes and on the epigenetic state of defined genomic loci, in defined cell types and in specific regions of the brain. These data, as well as findings from patient-derived tissue, have also begun to reveal alterations of epigenetic mechanisms in the pathophysiology and treatment of mood disorders. We summarize growing evidence supporting the notion that selectively targeting chromatin-modifying complexes, including those containing histone deacetylases (HDACs), provides a means to reversibly alter the acetylation state of neuronal chromatin and beneficially impact neuronal activity-regulated gene transcription and mood-related behaviors. Looking beyond current knowledge, we discuss how high-resolution, whole-genome methodologies, such as RNA-sequencing (RNA-Seq) for transcriptome analysis and chromatin immunoprecipitation-sequencing (ChIP-Seq) for analyzing genome-wide occupancy of chromatin-associated factors, are beginning to provide an unprecedented view of both specific genomic loci as well as global properties of chromatin in the nervous system. These methodologies when applied to the characterization of model systems, including those of patient-derived induced pluripotent cell (iPSC) and induced neurons (iNs), will greatly shape our understanding of epigenetic mechanisms and the impact of genetic variation on the regulatory regions of the human genome that can affect neuroplasticity. Finally, we point out critical unanswered questions and areas where additional data are needed in order to better understand the potential to target mechanisms of chromatin-mediated neuroplasticity for novel treatments of mood and other psychiatric disorders.

The Mendelian disorders of chromatin machinery: Harnessing metabolic pathways and therapies for treatment

Identification of Novel Mendelian Disorders of the Epigenetic Machinery (Mdems)-Associated Functional Mutations and Neurodevelopmental Disorders.

Delineation of a Human Mendelian Disorder of the DNA Demethylation Machinery: TET3 Deficiency.

Epigenetic mechanisms in mood disorders: targeting neuroplasticity

Small molecule modulators of chromatin remodeling: from neurodevelopment to neurodegeneration

Chromatin gatekeeper and modifier CHD proteins in development, and in autism and other neurological disorders

Chromatin Organization in Myelodysplastic Syndrome

Epigenetic Modifiers: Exploring the Roles of Histone Methyltransferases and Demethylases in Cancer and Neurodegeneration

Histone modifications in Duchenne muscular dystrophy: pathogenesis insights and therapeutic implications

Histone Lysine Methylation and Congenital Heart Disease: from Bench to Bedside (Review)

Chromodomain Helicase DNA-Binding Proteins in Stem Cells and Human Developmental Diseases

The interplay between DNA and histone methylation: molecular mechanisms and disease implications

De novo mutations in MSL3 cause an X-linked syndrome marked by impaired histone H4 lysine 16 acetylation

Histone Methyltransferases: Novel Targets for Tumor and Developmental Defects.

Methylation Across the Central Dogma in Health and Diseases: New Therapeutic Strategies

A peep into mitochondrial disorder: multifaceted from mitochondrial DNA mutations to nuclear gene modulation

Treatability of the KMT2‐Associated Neurodevelopmental Disorders Using Antisense Oligonucleotide‐Based Treatments

Developing therapeutic approaches for metachromatic leukodystrophy

Mitotic Block and Epigenetic Repression Underlie Neurodevelopmental Defects and Neurobehavioral Deficits in Congenital Heart Disease

variants leading to epigenetic machinery dysfunction are associated with a neurodevelopmental disorder

Distinct disease mutations in DNMT3A result in a spectrum of behavioral, epigenetic, and transcriptional deficits